# US 2016/0354327 A1 · Compound for treating cancer and diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354327 A1
- Document ID: US20160354327A1
- Status: Published application
- Kind: A1
- Application number: 15/173,628
- Filed: 2016-06-04
- Published: 2016-12-08
- Earliest claimed: 2011-01-27
- Assignees: City of Hope
- Applicants: City of Hope
- Inventors: Samuel RAHBAR; James L. Figarola; Christopher Lincoln; David Horne; Rachael Mooney; Monika Polewski; George Somlo; Lixin Yang
- Web page: https://patentgrep.com/patent/US20160354327A1

## CPC

- A61K 31/17: having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64)
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 229/00: Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.

## Claims

### Claim 1

A method of treating a cancer in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of 1,3-bis (3,5-dichlorophenyl) urea (COH-SR4),a salt thereof, or stereoisomers thereof, wherein the cancer is selected from the group consisting of melanoma, and lung cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cancer is melanoma.

### Claim 3 (depends on 2)

The method of claim 2, wherein the melanoma is metastatic melanoma.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cancer is lung cancer.

### Claim 5 (depends on 4)

The method of claim 4, wherein the lung cancer is non-small cell lung cancer.

### Claim 6 (depends on 1)

The method of claim 1, wherein the lung cancer is metastatic lung cancer.

### Claim 7 (depends on 2)

The method of claim 2, wherein the pharmaceutical composition further comprising one or more second anticancer agents selected from the group consisting of TMZ, SN38, CPT-11, and 5-FU.

### Claim 8 (depends on 1)

The method of claim 1, further comprising administering chemotherapy to the subject.

### Claim 9 (depends on 2)

The method of claim 2, further comprising administering chemotherapy to the subject.

### Claim 10 (depends on 4)

The method of claim 4, further comprising administering chemotherapy to the subject.

### Claim 11 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered by topical administration, mucosal administration, oral administration, nasal administration, vaginal administration, rectal administration, parenteral administration, transdermal administration, intravenous injection, subcutaneous administration, intramuscular injection, inhalation, or ophthalmic administration.

### Claim 12 (depends on 2)

The method of claim 2, wherein the pharmaceutical composition is administered by topical administration, mucosal administration, oral administration, nasal administration, vaginal administration, rectal administration, parenteral administration, transdermal administration, intravenous injection, subcutaneous administration, intramuscular injection, inhalation, or ophthalmic administration.

### Claim 13 (depends on 4)

The method of claim 4, wherein the pharmaceutical composition is administered by topical administration, mucosal administration, oral administration, nasal administration, vaginal administration, rectal administration, parenteral administration, transdermal administration, intravenous injection, subcutaneous administration, intramuscular injection, inhalation, or ophthalmic administration.

### Claim 14 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered at a daily dose of about 0.005 to about 25 mg/kg, about 0.01 to about 10 mg/kg, or about 0.05 to about 1 mg/kg, body weight of COH-SR4, a salt thereof, or stereoisomers thereof.

### Claim 15 (depends on 2)

The method of claim 2, wherein the pharmaceutical composition is administered at a daily dose of about 0.005 to about 25 mg/kg, about 0.01 to about 10 mg/kg, or about 0.05 to about 1 mg/kg, body weight of COH-SR4, a salt thereof, or stereoisomers thereof.

### Claim 16 (depends on 4)

The method of claim 4, wherein the pharmaceutical composition is administered at a daily dose of about 0.005 to about 25 mg/kg, about 0.01 to about 10 mg/kg, or about 0.05 to about 1 mg/kg, body weight of COH-SR4, a salt thereof, or stereoisomers thereof.
